Minerva Neurosciences, Inc(NERV)

Description: Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Drugs Psychoactive Drugs Neuroscience Parkinson's Disease Schizophrenia Neurochemistry Treatment Of Parkinson's Disease Major Depressive Disorder Antidepressants Ketones Depressive Disorder Central Nervous System Disease Insomnia Treatment Of Major Depressive Disorder Dopamine Investigational New Drug Treatment Of Central Nervous System Diseases

---

Home Page: www.minervaneurosciences.com

NERV Technical Analysis

1601 Trapelo Road
Waltham, MA 02451
United States
Phone: 617 600 7373

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)